- Credit Suisse downgraded Immunovant Inc IMVT to Underperform from Neutral and lowered the price target to $7 from $12.
- Analyst Tiago Fauth says that the downgrade reflects ongoing clinical and regulatory uncertainties for IMVT-1401 owing to safety concerns, likely extended clinical timelines with no clear value-driving catalysts in the next 12-months.
- According to the analyst, the $200M equity investment from Roivant Sciences has significantly reduced near-term M&A expectations as well.
- In March, Roivant revealed in an SEC filing to acquire all the shares in Immunovant.
- Price Action: IMVT shares are down 23.5% at $8 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorBiotechNewsShort IdeasDowngradesHealth CarePrice TargetOfferingsSmall CapAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in